awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q58714439
Q58714439
Item
http://www.wikidata.org/entity/Q58714439
Q58714439
about
Q58714439
Item
http://www.wikidata.org/entity/Q58714439
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
type
Item
P1433
Q58714439-D1EE0595-EF88-4E91-A66B-7CA223230A5A
P2093
Q58714439-2FFDEDC1-03C9-4998-86D5-A3C09DF25FA7
Q58714439-509EBA65-4458-4D20-BA4B-31BDF290035A
Q58714439-A7DA811C-3847-4C3C-B07B-97E11B949B30
Q58714439-B78B7577-B24D-4D77-BEAF-F9BC73F4988B
Q58714439-FD2AC6BC-F4D8-4E5C-BF25-CEE27331388F
P2860
Q58714439-067FAD14-E6A5-450C-B0E5-97D7CFD4DFDB
Q58714439-0DABE33B-8FCC-424D-AED9-898FB6225841
Q58714439-0DC96787-9045-420D-9464-F6A9B5F4E8CA
Q58714439-9E24A742-1A42-494E-ADBA-5D43575F4C34
Q58714439-A5663318-47A6-43E4-A16F-8EB657F74342
Q58714439-BC80B5FE-3E5B-45BE-ABBF-867B7FAAB77A
Q58714439-C809CE4C-7D10-4318-B70D-620D9A0F9526
Q58714439-CCCB8B54-B11E-4788-A6C6-F2BC3411BCC9
Q58714439-F5FCA30C-BE12-4081-AE16-D669B1EFCA21
Q58714439-F86FB712-0B2A-41E6-9A6D-AFFA226F39D9
P304
Q58714439-A92DAF51-7377-4C06-9BEB-A935F6636CA0
P31
Q58714439-30EF0EAD-1D09-461F-9734-A7D8BBA8428C
P356
Q58714439-E4255A94-D410-496F-8076-9C3CC1206AC0
P433
Q58714439-5D8DA036-57C7-415F-8ADE-9670B5D50976
P478
Q58714439-6D69D00C-FD4D-4CF3-A95F-1F24278D8C9F
P577
Q58714439-881E1994-930E-4BFE-B829-93192204032D
P698
Q58714439-16036329-8C6F-4C27-B97A-7757A53362B3
P932
Q58714439-EC05DC59-C8E3-44A8-9BE4-A3F59D4EDF76
P356
J.ISSN.1009-3419.2018.09.02
P1433
Zhongguo fei ai za zhi
P2093
Junjing Yin
http://www.w3.org/2001/XMLSchema#string
Kaoxiang Sun
http://www.w3.org/2001/XMLSchema#string
Sha Liu
http://www.w3.org/2001/XMLSchema#string
Xiaoyan Lv
http://www.w3.org/2001/XMLSchema#string
Xiucheng Yang
http://www.w3.org/2001/XMLSchema#string
P2860
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Cancer statistics in China, 2015.
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
P304
663-669
http://www.w3.org/2001/XMLSchema#string
P31
scholarly article
P356
10.3779/J.ISSN.1009-3419.2018.09.02
http://www.w3.org/2001/XMLSchema#string
P433
9
http://www.w3.org/2001/XMLSchema#string
P478
21
http://www.w3.org/2001/XMLSchema#string
P577
2018-09-20T00:00:00Z
http://www.w3.org/2001/XMLSchema#dateTime
P698
30201064
http://www.w3.org/2001/XMLSchema#string
P932
6136998
http://www.w3.org/2001/XMLSchema#string